How much does retatrutide cost, and why do the prices vary so much?

People search for “retatrutide cost” even though the drug has no price. Eli Lilly has not set one, because retatrutide is investigational and not FDA-approved. What people are actually pricing is a mix of online listings, clinic programs and stories passed around forums. This page sorts those out: the listing figures people are seeing (dated, from one storefront we checked), why the numbers vary so much, what Lilly has said about timing, and what reporting shows buyers are getting for their money. It is a cost explainer, not a recommendation to buy anything.

Evidence level on this page: the drug itself has been studied in large randomized human trials run by Lilly. The cost information is a different kind of evidence: product listings, company statements and news reporting. The real-world data on people using products bought outside trials cited here comes from an observational preprint, reported by Medscape, not from a trial.

How much does retatrutide cost?

There is no official retatrutide price, because Lilly has not brought it to market; its trial announcements describe results and plans, not pricing (Lilly, July 23, 2026). The numbers people see are listings from sellers. The storefront this site links to in its “Where it’s sold” card listed retatrutide at $172 for one month, or $127 a month on a three-month plan, on its product page when we checked on October 12, 2026. It describes the product as an injectable vial of retatrutide with vitamin B12, offered in several strengths, a combination that does not appear in Lilly’s trial announcements. We did not check prices at checkout.

That gives a “retatrutide price per month” figure, but it is a price for that seller’s product, not for Lilly’s drug. The documented routes to Lilly’s own retatrutide are its clinical trials and a limited expanded access program (Reuters, August 3, 2026), so a price you see online is attached to a product whose contents you are taking on trust.

What are the ways to get retatrutide, and what does each cost?

There are four routes people talk about, and they differ far more in what you actually get than in price. The table compares them on what is known, with the source for each row.

Sources: ClinicalTrials.gov, NCT07165028 and NCT07629401; Reuters, August 3, 2026; Medscape, August 26, 2026; storefront listing as checked October 12, 2026.

Why do retatrutide prices vary so much?

Retatrutide prices vary because sellers are not selling the same thing. With no approved product, there is no reference price and no standard product, so each seller sets its own. Four differences show up in what we checked and in recent reporting:

• What is in the vial. The storefront we checked pairs retatrutide with vitamin B12. A preprint covered by Medscape found products recorded in medical notes as blends with other unapproved compounds, including cagrilintide, BPC-157, NAD+ and IGF-1 analogues, none of which have been tested together in a trial (Medscape, August 26, 2026).
• Plan length. The same storefront charges less per month on a three-month plan than on a single month, so the “monthly price” depends on how much you commit to up front.
• Who is selling it. In that preprint, people using retatrutide outside trials mostly got it through online or telehealth vendors (57.4%) and compounding pharmacies (29.4%) (Medscape, August 26, 2026). CBS News found med spas and wellness clinics advertising retatrutide programs, including discount offers, and one clinic charging noticeably more for its retatrutide program than for the approved weight-loss drugs it also offered (CBS News, June 8, 2026).
• Bundled services. A clinic program may fold visits or check-ins into its price, while a storefront listing is the product price alone. Comparing the two directly can mislead in either direction.

One thing a low or high price does not tell you is what is in the product. The FDA says unapproved GLP-1 products bought online could contain the wrong ingredients, or too little, too much or none of the active ingredient, and it lists “prices that seem too good to be true” among its red flags (FDA, updated October 1, 2026). For the practical checks people use to judge a seller, see Peptides in Review’s guide on how to tell if a peptide vendor is legit.

When will retatrutide be available in the USA?

Lilly has not given an availability date. What it has said is that it plans to submit retatrutide to the FDA for U.S. approval in the first quarter of 2027, after it finishes the manufacturing and quality data package that a submission requires (Lilly, July 23, 2026). A submission starts the FDA’s review; it is not an approval, and the review itself takes time, so no one can honestly name a launch month yet. A launch price would only come after that. Until then, PeptideAgent’s retatrutide cost page lists no lawful price while the drug is investigational, and notes that clinical trial participants typically receive the drug at no cost.

How do you get retatrutide?

The documented routes to Lilly’s own retatrutide today are a clinical trial or Lilly’s expanded access program. ClinicalTrials.gov lists a Lilly-sponsored retatrutide (research code LY3437943) study as recruiting: SYNERGY-Outcomes, a phase 3 trial comparing retatrutide, tirzepatide and placebo in adults with metabolic dysfunction-associated steatotic liver disease (NCT07165028). Entry criteria differ by study. The expanded access program is narrow: a treating physician applies on a patient’s behalf, and the patient must be an adult with a BMI of 35 or more despite the highest available dose of chronic weight-management therapy, have at least two serious obesity-related complications, and be unable to join a trial (ClinicalTrials.gov, NCT07629401; Reuters, August 3, 2026). An endocrinologist quoted by The Guardian called qualifying “so unbelievably difficult” (The Guardian, August 31, 2026).

Where are people getting retatrutide?

Most people using retatrutide outside a trial are getting it from online sellers, telehealth vendors, clinics and compounding pharmacies, not from Lilly. In the health-record preprint covered by Medscape, 71.2% of users with a documented source got purported retatrutide outside trials, and use outside trials grew about 1.8-fold per quarter from October 2023 to March 2026 (Medscape, August 26, 2026). The Guardian described a buyer who ordered from sellers in China after reading about the drug in the news and on Reddit forums (The Guardian, August 31, 2026).

Is cheaper online retatrutide the same as Lilly’s drug?

No. Lilly calls what is sold on the black market “entirely unverified” (Lilly, August 12, 2026). Early data on what buyers get comes from the Medscape-covered preprint: people using retatrutide from outside trials lost about 7.2% of their weight at 6 to 12 months, against 15.5% for trial participants in the same health records, while still showing a heart-rate rise (Medscape, August 26, 2026). It is observational, with short follow-up, so it cannot prove why. But it is a reminder that the trial results people quote are for Lilly’s drug, given on a supervised schedule. For what those trials recorded on side effects, see retatrutide side effects.

What the community is saying about the cost

We do not have our own community-tracker data for retatrutide yet, so this section summarizes published reporting rather than quoting posts.

• The demand is huge, and it is social. The Guardian reported that a Reddit community devoted to retatrutide gets more than 179,000 visits a week and hosts a beginner’s guide to finding it outside a trial that urges readers to vet sellers heavily (The Guardian, August 31, 2026). A former FDA criminal investigations official quoted there said the drug has been popularized through podcasts and politicians.
• The “cheaper than the approved drugs” pitch. CBS News found a physician promoting retatrutide as less expensive and more effective than the best weight-loss drugs on the market (CBS News, June 8, 2026). The catch is that the comparison is between a labeled, approved medicine and a product whose contents are unknown, and the Medscape-covered preprint found roughly half the trial-level weight loss.
• The hidden costs are medical. CBS reported that exposures tracked by America’s Poison Centers averaged about 95 a month in the first four months of 2026, up 265% from the last four months of 2025, and described a man who went to urgent care three times after injecting a product bought online (CBS News, June 8, 2026). The Guardian noted that health officials in Victoria, Australia, reported six cases of acute liver toxicity in people who used a product labeled as retatrutide (The Guardian, August 31, 2026).
• The waiting argument. An endocrinologist quoted by The Guardian said she would recommend the drug, but not through the gray market, and advised waiting until it reaches the market.

What does an approved alternative cost?

The approved medicines closest to retatrutide are tirzepatide (Zepbound, Mounjaro) and semaglutide (Wegovy, Ozempic), and both makers now sell them directly to cash-pay patients at published prices. Our guide to what a GLP-1 costs without insurance lists those prices with sources, and our explainer on branded vs compounded GLP-1 access in 2026 covers how the routes differ. For one table that puts peptide and GLP-1 costs side by side across the network, see The Treatment Report’s 2026 peptide and GLP-1 cost index, and for the full background on the drug, its retatrutide overview.

What is the honest bottom line on retatrutide cost?

The honest answer is that retatrutide does not have a price yet, only listings. The figures online are prices for sellers’ products, which vary with what is in the vial, plan length and who is selling, and none of them buys Lilly’s trial drug. If a price is the deciding factor, the useful comparison today is with the approved medicines, whose prices are published and whose contents are not in question.

Status: Investigational; not FDA-approved. Lilly plans to submit it for approval in Q1 2027. What this status means.

Educational information only, not medical advice. Listing prices are as shown on the storefront’s product page on October 12, 2026 and can change; checkout prices were not checked. Trial and reporting details are as published in the cited sources as of October 12, 2026.